《神州民企》康希諾生物（００６８５）啟動兩疫苗臨床試驗

　　《經濟通通訊社２３日專訊》康希諾生物（０６８５）（滬：６８８１８５）公布，兩項疫
苗啟動臨床試驗。
　
　　該集團指，開發的吸附無細胞百（組分）白破聯合疫苗（６歲及以上人群用）於近日正式啟
動ＩＩ╱ＩＩＩ期臨床試驗，並完成ＩＩ期臨床試驗首例受試者入組。此外，該集團開發的重組
脊髓灰質炎疫苗近日於印尼正式啟動Ｉ╱ＩＩ期臨床試驗，並完成Ｉ期臨床試驗首例受試者入組
。（ｗｈ）

【你點睇？】特朗普指不排除使用武力奪取格陵蘭及巴拿馬運河，你認為言論會否加劇美國與盟友間的不信任？► 立即投票

返回全日新聞

回頁頂

經濟通
強化版MQ
強化版TQ
財曆
Mobile
Web

客務熱線︰(852) 2880 7004 客務郵箱︰cs@etnet.com.hk
關於我們 | 產品服務 | 廣告查詢 | 聯絡我們 | 私隱政策 | 使用條款 | 網站導航 | 有用連結 | RSS新聞

Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.

《經濟通》所刊的署名及／或不署名文章，相關內容屬作者個人意見，並不代表《經濟通》立場，《經濟通》所扮演的角色是提供一個自由言論平台。